Precigen, Inc. (PGEN)
| Market Cap | 1.58B +243.5% |
| Revenue (ttm) | 31.60M +652.1% |
| Net Income | -383.42M |
| EPS | -1.17 |
| Shares Out | 356.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,615,452 |
| Open | 4.540 |
| Previous Close | 4.600 |
| Day's Range | 4.360 - 4.630 |
| 52-Week Range | 1.260 - 5.465 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 9.33 (+111.09%) |
| Earnings Date | May 13, 2026 |
About PGEN
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops pro... [Read more]
Financial Performance
In 2025, Precigen's revenue was $9.68 million, an increase of 146.73% compared to the previous year's $3.93 million. Losses were -$429.64 million, 240.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price target is $9.33, which is an increase of 111.09% from the latest price.
News
Precigen price target raised to $11 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $11 from $10 and keeps a Buy rating on the shares post the Q1 report. The firm says Papzimeos…
Precigen price target raised to $11 from $9 at Citizens
Citizens raised the firm’s price target on Precigen (PGEN) to $11 from $9 and keeps an Outperform rating on the shares. The firm is impressed by the strength of the…
Precigen reports Q1 EPS (2c) vs. (18c) last year
Reports Q1 revenue $23.25M, consensus $20.8M. “We are thrilled with the strength of the PAPZIMEOS launch and the pace of revenue growth as we drive broad commercial success across the…
Precigen Earnings Call Transcript: Q1 2026
PAPZIMEOS achieved $21.6M in Q1 2026 revenue, driven by rapid adoption, broad payer coverage, and strong community uptake. Cash position is solid, with operations funded through 2026, and further clinical and regulatory milestones are expected this year.
Precigen Reports First Quarter 2026 Financial Results and Business Updates
PAPZIMEOS™ launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the US Patient hub enrollment continues to gain tr...
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
GERMANTOWN, Md., May 7, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve th...
Precigen sees Q1 revenue exceeding $18M, consensus $20.8M
“In the short time since early and full approval, the standard-of-care first-line treatment is seeing tremendous progress,” said Precigen’s (PGEN) President and CEO, Helen Sabzevari, during a conferen...
Precigen sees ‘robust uptake’ in usage of Papzimeos since its launch
Precigen (PGEN) announces it has seen “robust uptake” in usage of Papzimeos since launching the immunotherapy in August 2025. Additionally, the company announced that the Centers for Medicare and Medi...
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Plans Underway to Expand Use to Pediatrics, Patient Redosing and European Approval Meg Flippin, Benzinga Staff Writer GERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. (NASDAQ:PGEN), a ...
Precigen Transcript: Fireside chat
PAPZIMEOS, the first immunotherapy for adult RRP, is driving a commercial transformation, with strong launch metrics, broad physician support, and robust payer access. The company is expanding its pipeline with pediatric trials, redosing studies, and new cancer indications leveraging its differentiated platform.
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...
Precigen jumps on Q1 outlook despite earnings miss
Precigen (PGEN) shares are trading up almost 26% at $3.91 after the company reported quarterly results. The biotech company reported $9.7M in revenue, missing consensus estimates by $3.8M, but highlig...
Precigen price target raised to $10 from $9 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $10 from $9 and keeps a Buy rating on the shares. The firm says Papzimeos sales are expected to…
Precigen price target raised to $9 from $8 at Citizens
Citizens raised the firm’s price target on Precigen (PGEN) to $9 from $8 and keeps an Outperform rating on the shares. Precigen reported Q4 updates highlighting strong early commercial traction…
Precigen Earnings Call Transcript: Q4 2025
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 revenue expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, while European expansion and pediatric trials are underway.
Precigen Reports Full Year 2025 Financial Results and Business Updates
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 PAPZI...
Options Volatility and Implied Earnings Moves Today, March 25, 2026
Today, several major companies are expected to report earnings: Cintas (CTAS), Jefferies (JEF), Paychex (PAYX), Winnebago Industries (WGO), Precigen (PGEN), Baozun (BZUN), PDD Holdings (PDD), Beyond M...
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Independent, expert-led consensus paper, sponsored by the Recurrent Respiratory Papillomatosis Foundation, reflects the recommendation of 16 leading physicians in the field of RRP Consensus paper reco...
Precigen Transcript: 44th Annual J.P. Morgan Healthcare Conference
A proprietary adenovirus platform enabled rapid development and full FDA approval of Pepcimeus for RRP, shifting care from surgery to a medical standard. Commercial launch saw swift market penetration, strong payer coverage, and broad physician adoption, with ex-U.S. expansion and cash flow positivity targeted by year-end.
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for adults with RRP PAPZIMEOS commercialization is well ...
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President ...
JPMorgan healthcare analysts hold an analyst/industry conference call
Healthcare Analysts assess the current hurdles and demand in the early phase of Papzimeos (PGEN) launch on an Analyst/Industry conference call to be held on December 3 at 11 am.
Precigen price target raised to $9 from $8.50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $9 from $8.50 and keeps a Buy rating on the shares post the Q3 report. The firm says the…
Precigen reports Q3 EPS ($1.06) vs. (9c) last year
EPS was impacted by non-cash items including the increase in the fair value of the warrant liabilities and the deemed dividend on preferred shares, for a combined impact of 95c…